Achievement of Early Deep Remission Predicts Better Long-Term Outcomes for Adalimumab-Treated Patients with Crohnʼs Disease: Data from EXTEND

MLA

Naijun Chen, et al. “Achievement of Early Deep Remission Predicts Better Long-Term Outcomes for Adalimumab-Treated Patients with Crohnʼs Disease: Data from EXTEND.” American Journal of Gastroenterology, vol. 105, Oct. 2010, pp. S434–35. EBSCOhost, https://doi.org/10.14309/00000434-201010001-01190.

APA

Naijun Chen, Jingdong Chao, Paul F. Pollack, Anne Camez, Jean-Frederic Colombel, Paul Rutgeerts, William J. Sandborn, Mei Yang, Roopal Thakkar, Parvez Mulani, & Kathleen Lomax. (2010). Achievement of Early Deep Remission Predicts Better Long-Term Outcomes for Adalimumab-Treated Patients with Crohnʼs Disease: Data from EXTEND. American Journal of Gastroenterology, 105, S434–S435. https://doi.org/10.14309/00000434-201010001-01190

Chicago

Naijun Chen, Jingdong Chao, Paul F. Pollack, Anne Camez, Jean-Frederic Colombel, Paul Rutgeerts, William J. Sandborn, et al. 2010. “Achievement of Early Deep Remission Predicts Better Long-Term Outcomes for Adalimumab-Treated Patients with Crohnʼs Disease: Data from EXTEND.” American Journal of Gastroenterology 105 (October): S434–35. doi:10.14309/00000434-201010001-01190.